Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03521154 · OUTCOME

Tumour Shrinkage by Blinded Independent Central Review (BICR)

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) · Source last updated 2026-08-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
% change from baseline
Interval / dispersion
Full Range
Time frame
Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months

What was measured

Depth of response (or tumour shrinkage or change in tumour size) was assessed using BICR responses in target lesions. The best change in tumour size is the largest decrease from baseline or the smallest increase from baseline in the absence of a reduction

Analysis population: Full analysis set

Groups in this outcome

Osimertinib

80mg once daily tablet

Placebo

Matching Placebo

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Osimertinib133
Placebo70

Reported measurements

Source class 1
Values in % change from baseline · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Osimertinib-43.3Not reported-100144Not reported
Placebo-21.9Not reported-10023Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        -100
        upper Limit
        144
        value
        -43.3
      2. group Id
        OG001
        lower Limit
        -100
        upper Limit
        23
        value
        -21.9
denoms
  1. counts
    1. group Id
      OG000
      value
      133
    2. group Id
      OG001
      value
      70
    units
    Participants
description
Depth of response (or tumour shrinkage or change in tumour size) was assessed using BICR responses in target lesions. The best change in tumour size is the largest decrease from baseline or the smallest increase from baseline in the absence of a reduction
dispersion Type
Full Range
groups
  1. description
    80mg once daily tablet
    id
    OG000
    title
    Osimertinib
  2. description
    Matching Placebo
    id
    OG001
    title
    Placebo
param Type
MEDIAN
population Description
Full analysis set
reporting Status
POSTED
time Frame
Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
title
Tumour Shrinkage by Blinded Independent Central Review (BICR)
type
SECONDARY
unit Of Measure
% change from baseline

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice